Executive Summary
A clinical-stage biotechnology sponsor was advancing a complex development program through an outsourced operating model. Internal CMC, Quality, Clinical Operations, clinical supply, Finance, and program leadership worked with a network of CROs, CDMOs, analytical laboratories, depots, logistics providers, and clinical sites. Each function and partner maintained useful records, but no single operating view connected the milestones required to keep the program ready.
The difficulty was not obtaining status. The sponsor received substantial status information. The difficulty was determining whether separate updates collectively supported the next program event. A manufacturing activity could remain on schedule while a testing deliverable, Quality Unit disposition, depot transfer, site-readiness requirement, or sponsor decision created a downstream constraint.
Gyan Solutions conducted a Pharmaceutical Operational Review around a representative clinical execution window and its supporting supply campaign. The review reconstructed the critical path from approved program assumptions through clinical-supply availability and site readiness, then tested how changes, evidence, ownership, and escalation moved across internal and external boundaries.
The engagement established an integrated readiness baseline, evidence-based milestone definitions, sponsor ownership for external dependencies, a structured exception process, and a tiered governance cadence. Existing CTMS, IRT/RTSM, quality, supply, finance, and vendor systems remained in place. The improvement came from connecting their operational outputs to one sponsor-level control model.
Program readiness was split across functions and partner updates
CMC, Quality, Clinical Operations, supply, CROs, CDMOs, labs, depots, logistics, and sites each had useful updates, but no single view showed whether the program could move as planned.
One sponsor-level readiness baseline
The client needed a practical control layer connecting milestone dates, evidence, ownership, downstream dependencies, exceptions, and decision points across internal teams and external partners.
Trial execution depended on aligned readiness
A change in manufacturing, testing, Quality Unit disposition, depot activity, site readiness, or partner delivery could affect clinical supply, site sequencing, vendor commitments, and leadership decisions.
Clarify readiness before recommending system changes
The review focused on the operating model first: what counted as ready, which source was authoritative, who owned each dependency, and how exceptions should move through governance.
Background
The client operated as the program sponsor while outsourcing substantial portions of manufacturing, testing, clinical execution, supply handling, and specialist services. This model provided access to experienced partners and flexible capacity, but the sponsor retained accountability for coordinating the overall development plan.
The network did not operate from one planning logic. The CDMO planned campaigns and deliverables. Clinical Operations managed CRO and site activity. Clinical supply managed demand, inventory, depot and distribution requirements. Quality controlled its review and disposition process. Finance tracked commitments and forecast effects. Each perspective was valid, but they did not always use the same baseline date, readiness definition, or escalation threshold.
As the program moved into a more execution-intensive stage, the cost of disconnected planning increased. A change in one partner milestone could affect clinical-supply availability, site sequencing, resource requirements, vendor spend, and leadership decisions. The sponsor needed a control layer capable of showing those effects without duplicating controlled records or intruding on functional decision rights.
Initial Observations
Functional plans were individually sound but not fully integrated. CMC, Quality, Clinical Operations, supply, and external partners maintained their own schedules, yet the handoffs between those schedules were not consistently governed as one critical path.
Partner status did not always equal sponsor readiness. A vendor could report a deliverable as complete or on track while the sponsor still lacked accepted evidence, a required decision, an available downstream resource, or confirmation that the next activity could begin.
Supply and site readiness were reviewed through separate lenses. Clinical-supply availability, depot positioning, shipment timing, IRT/RTSM configuration status, and site readiness were visible, but not consistently reconciled against the same execution window.
Date changes were communicated but their consequences were manually interpreted. Teams understood that a milestone had moved; they then had to determine which downstream activities, forecasts, decisions, and vendor commitments were affected.
Exceptions lived in communication channels rather than one controlled operating queue. Email, meeting notes, and partner trackers recorded issues, but there was no persistent view of the operational effect, sponsor owner, next action, escalation point, and closure condition.
Leadership reporting was accurate but labour-intensive. The cross-functional team assembled a current view before governance meetings, but much of that effort had to be repeated because the underlying dependency view was not continuously maintained.
Review & Design Approach
The review used an integrated development-operations lens. Gyan selected one upcoming execution window and traced every material dependency required to support it. The team worked backward from the sponsor’s need-by date and forward from the earliest upstream deliverables to identify where timing, evidence, ownership, or decision-making could break alignment.
The scope remained operational. Gyan did not determine clinical strategy, interpret scientific or safety data, set product specifications, make Quality Unit disposition decisions, or advise on regulatory conclusions. Approved requirements and formally recorded functional decisions entered the readiness model as inputs.
Trace manufacturing, testing, Quality Unit disposition, clinical-supply, depot, logistics, CRO, and site-readiness dependencies.
Establish the governing program milestone, approved assumptions, and sponsor need-by date.
Identify the authoritative source and completion evidence for each milestone without creating a parallel controlled record.
Test whether milestone dates across partner and sponsor plans reconciled to the same operating baseline.
Follow representative changes downstream to expose schedule, supply, resource, vendor, and decision consequences.
Map the partner owner, sponsor owner, decision authority, escalation route, and closure condition for each material exception.
Compare detailed workstream evidence with the information used at cross-functional and executive governance levels.
PHARMACEUTICAL GOVERNANCE BOUNDARY
Quality, Clinical, Safety, Medical, CMC, and Regulatory functions retained their established authorities and systems. The operating model connected their approved outputs and recorded statuses; it did not replace, reinterpret, or circumvent controlled decisions.
Key Findings
CENTRAL FINDING
The sponsor did not lack systems, partner reports, or functional expertise. It lacked an integrated sponsor-level readiness model connecting authoritative records to the critical path, downstream dependencies, accountable action, and governance decisions.
The critical path existed across organizations, not inside one plan.
No individual partner or function could represent complete program readiness because the next execution window depended on outputs crossing several organizational boundaries.
A green workstream status could coexist with a program-level constraint.
. Functional reporting reflected local delivery. Sponsor readiness required confirmation that the output had been accepted, its evidence was available, and the downstream function could proceed.
Milestone dates were weaker than evidence-based readiness criteria.
A planned or reported date did not establish readiness by itself. Each milestone needed a defined event, authoritative source, acceptance evidence, accountable owner, and affected dependency.
External responsibility did not remove sponsor accountability.
Where a partner performed the work, the sponsor still needed an internal owner responsible for monitoring the dependency, assessing operational effects, coordinating responses, and driving closure.
Governance meetings were compensating for a missing control layer.
Manual meeting preparation reconciled plans temporarily, but did not maintain the integrated baseline or provide continuous visibility into newly created exceptions.
A broad system replacement would have added risk without resolving the operating model.
The issue was not where controlled records were stored. It was how selected operational statuses were translated into cross-functional readiness and action.
Decisions & Direction
The sponsor adopted a control model based on an integrated readiness baseline and three levels of governance. Workstream teams continued to manage detailed execution; cross-functional governance managed dependencies and exceptions; executive governance addressed material decisions and trade-offs.
Preserve CTMS, IRT/RTSM, quality, supply, finance, and vendor systems as the authoritative sources for their respective records.
Create one sponsor-level critical-path baseline connecting CMC, Quality, clinical supply, Clinical Operations, and external-partner milestones.
Define each critical milestone through an event, authoritative source, acceptance evidence, sponsor owner, target date, and downstream dependency.
Assign separate responsibility for performing the work, owning the sponsor dependency, approving any controlled decision, and driving an exception to closure.
Standardize partner reporting around milestone variance, evidence available, downstream effect, recovery action, owner, and decision required.
Maintain one exception register for material schedule, supply, deliverable, evidence, ownership, and decision risks.
Use a rolling readiness horizon so near-term execution received detailed control while later milestones remained visible at an appropriate level.
Redesign governance meetings so each level addressed only the decisions, exceptions, and accountabilities appropriate to it.
Implementation
Integrated Readiness Baseline
The team established a sponsor-level baseline anchored to the required clinical execution window. Critical CMC, testing, Quality Unit disposition, supply, depot, logistics, CRO, and site-readiness milestones were linked according to their actual predecessor and successor relationships. The baseline did not copy every line from every partner plan. It selected the milestones whose movement could change supply availability, site execution, sponsor decisions, resource requirements, or material vendor commitments.
Evidence-Based Readiness Definitions
For each critical milestone, the sponsor defined what had to occur, which authoritative source recorded it, what evidence demonstrated completion, who confirmed operational acceptance, and which downstream activity could then proceed. Three readiness states were used: ready, at risk, and blocked. The status reflected the full dependency condition rather than the optimism of an individual workstream. An item could not remain ready if an unresolved dependency prevented the next required activity.
Clinical-Supply and Site-Readiness Reconciliation
Clinical-supply availability was reconciled with the sponsor’s operating assumptions for depot positioning, shipment timing, inventory availability, relevant dating constraints, IRT/RTSM readiness, and site sequencing. This created one view of whether supply and sites would be ready in the same window. The model used formally recorded Quality Unit disposition as a gating status. It did not predict, accelerate, or reinterpret disposition; it showed the operational consequences of the recorded status for supply movement and downstream readiness.
Sponsor and Partner Accountability
A dual-ownership structure was introduced. The performing owner remained responsible for the underlying deliverable. A named sponsor owner remained responsible for dependency visibility, internal coordination, recovery planning, escalation, and closure. Partner updates were standardized around what changed, the variance from plan, evidence available, downstream effect, recovery action, sponsor decision required, and next committed date. This made updates comparable across organizations without requiring partners to adopt the sponsor’s internal systems.
Exception and Change Control
Material variances entered one exception register with a concise problem statement, affected milestone, operational consequence, owner, required action, due date, escalation threshold, decision authority, and closure evidence. When an upstream date changed, the cross-functional team assessed downstream effects before accepting the revised baseline. This prevented isolated schedule changes from being absorbed without visibility into their program, supply, resource, or vendor consequences.
Tiered Governance and Visibility
Workstream reviews managed detailed execution. The cross-functional readiness review focused on critical dependencies, changed dates, at-risk or blocked milestones, and overdue actions. Executive governance received only material program effects, decision options, accountable owners, and required decision dates. A lightweight readiness view consolidated the limited fields required for this governance model. It drew from approved reports and structured partner updates while controlled records remained in the appropriate clinical, quality, supply, finance, and vendor systems.
Operating Change
| Before the review | After implementation |
|---|---|
| Separate functional and partner plans | One sponsor-level critical-path baseline |
| Milestone status based primarily on dates | Readiness based on event, source, evidence, owner, and dependency |
| Supply and site readiness reviewed separately | Supply and site assumptions reconciled to one execution window |
| Partner updates described local activity | Updates showed variance, downstream effect, recovery action, and decision required |
| Exceptions distributed across email and meetings One persistent exception and escalation register | One persistent exception and escalation register |
| Status reconstructed before governance meetings | A continuously maintained readiness view |
| All details elevated to leadership | Tiered governance matched information to decision authority |
Impact
The engagement gave the sponsor a clearer and more disciplined view of program readiness across internal functions and outsourced partners. The organization retained its specialized systems and functional controls while improving how selected operational information supported cross-functional action.
One sponsor-level readiness view. CMC, Quality, clinical supply,
Clinical Operations, and partner milestones were discussed against one critical path and one set of dependency definitions.
Earlier visibility into downstream effects.
Date changes, missing evidence, and partner variances were connected to supply, site, resource, vendor, and decision consequences before the next governance meeting.
Stronger alignment between clinical supply and site readiness.
The sponsor could see whether supply availability, depot and distribution activity, system readiness, and site sequencing supported the same execution window.
Clearer sponsor accountability for outsourced work.
External responsibility remained visible, but every material dependency and exception also had a named internal owner responsible for coordination and closure.
More decision-focused governance.
Meetings shifted from compiling updates to reviewing variances, resolving dependencies, confirming recovery actions, and making decisions at the appropriate level.
More consistent partner oversight.
Partners reported material milestones through a common operational structure while continuing to use their established systems and detailed work practices.
Existing systems and controlled records preserved.
The readiness layer supported sponsor oversight without becoming a substitute CTMS, IRT/RTSM, quality, supply, finance, or vendor record.
Why This Held
It was anchored to a real execution window. The model was built from the actual sequence of work required to support the program, not from a generic dashboard template.
It treated readiness as an evidence-based condition. A date or local completion statement was insufficient unless the required event, evidence, acceptance, and downstream dependency aligned.
It reflected sponsor accountability. External partners remained responsible for their work, while internal owners remained responsible for understanding and managing sponsor-level consequences.
It respected controlled decision rights. Quality, Clinical, Safety, Medical, CMC, and Regulatory functions retained their authorities and authoritative records.
It connected supply and clinical execution. The model reconciled the operating assumptions that had to be true at the same time for the execution window to remain viable.
It separated oversight from system replacement. The sponsor gained a usable control layer without forcing specialized functions or partners into another broad platform.
It made escalation proportionate. Workstream teams handled routine execution, cross-functional governance handled dependencies, and leadership addressed only material decisions and trade-offs.
CONFIDENTIALITY
The client’s identity and selected program, product, partner, timeline, location, and system details have been withheld or generalized. The case study describes the completed pharmaceutical-operations engagement without identifying the client, its personnel, or its product candidates.